BRPI0006823B8 - composição farmacêutica estabilizada, preparação de injeção, e kit comercial - Google Patents

composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Info

Publication number
BRPI0006823B8
BRPI0006823B8 BRPI0006823A BRPI0006823A BRPI0006823B8 BR PI0006823 B8 BRPI0006823 B8 BR PI0006823B8 BR PI0006823 A BRPI0006823 A BR PI0006823A BR PI0006823 A BRPI0006823 A BR PI0006823A BR PI0006823 B8 BRPI0006823 B8 BR PI0006823B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
injection preparation
commercial kit
stabilized pharmaceutical
stabilized
Prior art date
Application number
BRPI0006823A
Other languages
English (en)
Portuguese (pt)
Inventor
Kasai Akihiro
Otomo Kazumi
Sawai Seiji
Original Assignee
Astellas Pharma Inc
Fujisawa Pharmaceutical Co
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0006823(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Fujisawa Pharmaceutical Co, Yamanouchi Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of BRPI0006823B1 publication Critical patent/BRPI0006823B1/pt
Publication of BRPI0006823B8 publication Critical patent/BRPI0006823B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0006823A 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial BRPI0006823B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
JPHEI11-187713 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (2)

Publication Number Publication Date
BRPI0006823B1 BRPI0006823B1 (pt) 2020-01-07
BRPI0006823B8 true BRPI0006823B8 (pt) 2021-05-25

Family

ID=16210881

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial
BR0006823-3A BR0006823A (pt) 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0006823-3A BR0006823A (pt) 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial

Country Status (28)

Country Link
US (2) US6774104B1 (enExample)
EP (1) EP1107777B1 (enExample)
JP (2) JP3381722B2 (enExample)
KR (1) KR100454784B1 (enExample)
CN (2) CN100352495C (enExample)
AR (1) AR024634A1 (enExample)
AT (1) ATE280583T1 (enExample)
AU (1) AU752265B2 (enExample)
BR (2) BRPI0006823B8 (enExample)
CA (1) CA2341568C (enExample)
CZ (1) CZ295720B6 (enExample)
DE (1) DE60015279T2 (enExample)
ES (1) ES2225161T3 (enExample)
HK (1) HK1040057B (enExample)
HU (1) HU229089B1 (enExample)
ID (1) ID29468A (enExample)
IL (2) IL141455A0 (enExample)
MX (1) MXPA01000601A (enExample)
NO (1) NO330353B1 (enExample)
NZ (1) NZ510290A (enExample)
OA (1) OA11601A (enExample)
PL (1) PL200141B1 (enExample)
PT (1) PT1107777E (enExample)
RU (1) RU2251411C2 (enExample)
TR (1) TR200100609T1 (enExample)
TW (1) TWI233805B (enExample)
WO (1) WO2001002002A1 (enExample)
ZA (1) ZA200101589B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
EP1525884B1 (en) 2002-07-31 2011-10-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003298662A1 (en) * 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
CA2558191C (en) * 2004-03-04 2011-01-04 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
US7514450B2 (en) * 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
EP2417986A1 (en) * 2004-11-22 2012-02-15 Anadis Ltd. Bioactive compositions
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
KR20080028942A (ko) * 2005-07-20 2008-04-02 교와 메덱스 가부시키가이샤 생체 시료 중의 펩티드의 안정화 방법
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN104968348B (zh) * 2012-05-22 2018-04-17 Paion英国有限公司 包含短效苯二氮杂*类化合物的组合物
US20140274994A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Stabilizing ceftolozane
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
ES2978920T3 (es) * 2013-06-05 2024-09-23 Univ British Columbia Compuestos antifibrogénicos, métodos y usos de los mismos
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
JP7109189B2 (ja) * 2014-05-29 2022-07-29 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド シクロペプチド系化合物の組成物およびその製造方法と使用
RU2732129C2 (ru) * 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
DK3240529T3 (da) * 2014-12-31 2022-02-28 Galenicum Health S L U Stabile farmaceutiske sammensætninger omfattende micafungin
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
AU2017376960B2 (en) 2016-12-16 2023-12-14 Baxter Healthcare Sa Micafungin compositions
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
AU681119B2 (en) * 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
WO1996011210A1 (en) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
DE69739532D1 (de) * 1996-03-08 2009-09-24 Astellas Pharma Inc Prozess für die deacylierung von zyklischen lipopeptiden.
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
DK1582204T3 (da) * 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
IL145188A0 (en) * 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
CN1179748C (zh) 2004-12-15
AR024634A1 (es) 2002-10-16
CN1315865A (zh) 2001-10-03
JP2002363097A (ja) 2002-12-18
HK1040057A1 (en) 2002-05-24
AU752265B2 (en) 2002-09-12
CN1636591A (zh) 2005-07-13
KR20010072903A (ko) 2001-07-31
ATE280583T1 (de) 2004-11-15
AU5572200A (en) 2001-01-22
US7112565B2 (en) 2006-09-26
KR100454784B1 (ko) 2004-11-05
HUP0103740A2 (hu) 2002-02-28
ES2225161T3 (es) 2005-03-16
DE60015279D1 (de) 2004-12-02
HUP0103740A3 (en) 2002-08-28
ID29468A (id) 2001-08-30
PT1107777E (pt) 2005-01-31
HK1080724A1 (zh) 2006-05-04
JP4691866B2 (ja) 2011-06-01
ZA200101589B (en) 2002-09-02
WO2001002002A1 (en) 2001-01-11
MXPA01000601A (es) 2002-04-08
CZ20011186A3 (cs) 2001-09-12
NO20010893L (no) 2001-04-24
OA11601A (en) 2004-07-30
NO20010893D0 (no) 2001-02-22
DE60015279T2 (de) 2005-05-25
CA2341568A1 (en) 2001-01-11
NO330353B1 (no) 2011-04-04
PL200141B1 (pl) 2008-12-31
EP1107777A1 (en) 2001-06-20
NZ510290A (en) 2003-07-25
US20040157769A1 (en) 2004-08-12
RU2251411C2 (ru) 2005-05-10
JP3381722B2 (ja) 2003-03-04
BRPI0006823B1 (pt) 2020-01-07
HK1040057B (zh) 2005-08-05
PL346297A1 (en) 2002-01-28
US6774104B1 (en) 2004-08-10
JP2003503462A (ja) 2003-01-28
IL141455A (en) 2006-12-31
IL141455A0 (en) 2002-03-10
TWI233805B (en) 2005-06-11
HU229089B1 (en) 2013-07-29
CZ295720B6 (cs) 2005-10-12
CA2341568C (en) 2011-10-25
EP1107777B1 (en) 2004-10-27
BR0006823A (pt) 2001-06-05
CN100352495C (zh) 2007-12-05
TR200100609T1 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
BRPI0006823B8 (pt) composição farmacêutica estabilizada, preparação de injeção, e kit comercial
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
TR200003256T2 (tr) P-38 mapkinaz engelleyicileri olan pirazol türevleri
BR0108679A (pt) Novos compostos
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
TR200200778T2 (tr) Pirazol türevleri.
BRPI0212726B8 (pt) compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
EA199900242A1 (ru) Аралкил- и аралкилиден-гетероциклические лактамы и имиды
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
BRPI0112859B8 (pt) análogos de somatostatina, composição farmacêutica, bem como uso dos referidos análogos
TR199901578T2 (xx) Klaritromisin form 0 kristali
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
DE69932424D1 (de) Melanocortin 1 rezeptorselektive verbindungen
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
BR0016133A (pt) Composto, formulação farmacêutica, e, uso de um composto
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2001072263A3 (de) Verwendung von ectoin oder ectoin-derivaten zum schutz der stressprotein in der haut
NO20020176D0 (no) Sykliske peptidderivater som inhibitorer for intergrin <alfa>v<beta>6
EP1284272A4 (en) ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
BR0302496A (pt) Composições farmacêuticas com atividade antibiótica
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto